Oculus Innovative Granted Reclassification for Microcyn-Based Advanced Wound Management Products in Europe
March 26, 2013 at 08:10 AM EDT
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS ) a healthcare company a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that is has been granted a reclassification of the company's CE Mark for the European formulation Dermacyn™ Wound Care. The reclassification was approved by the British Standards